Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Retiremesouthon Jan 14, 2021 2:15pm
259 Views
Post# 32298322

RE:RE:Steps forward and still needed

RE:RE:Steps forward and still neededThis was sent out to investors who have signed up for updates after the NR:

Dear Stakeholder;

Attached is a press release announcing a new initiative to apply the VMS heart analysis technology to companion animals. Here is some background:

1. The versatility of the VMS system to be able to analyze very misshapen and enlarged hearts makes it an excellent technology to attempt to characterize animal hearts (which really are not all that different).
2. Initial testing in dogs has shown the same heart databases that work for human hearts work well for canine hearts and so the results from echocardiography are identical to MRI results in the few studies made available to us by the North Carolina State University (NCSU) veterinary school.
3. Hence, we have established a collaboration with the echocardiograph team at NCSU led by Dr. Bruce Keene to do a proper study showing the accuracy and reproducibility of the VMS in echo in dogs as compared to MRI.
4. There are no regulatory hurdles to apply the VMS to animals and so we will be able to begin marketing the VMS for companion animal use as soon as the study completes. It should not take long, but of course timing in the current pandemic setting is difficult to determine.
5. I was amazed at the number of people who have adopted a pet in the last year as COVID has made everyone less connected. I also know from my friends with pets that they are a true member of the family and are expected to have the same healthcare as the human members. When we started to explore the companion animal market we heard the same issues from vets as we hear from doctors who treat people - lack of accuracy, reproducibility and ease of analysis for echo and cost, sedation and lack of access to MRI. The VMS overcomes all these limitations.
6. We continue to be focused on cardiac diagnosis in children and adults, but since there are minimal adaptations needed to apply the VMS to companion animals and we have excellent collaborators willing to verify the system for this application, we have elected to expand our product offering.
7. Horses would be the logical next species to address as they also have heart problems. A friend of mine raises hypoallergenic horses and sells them for a lot of money. His vet spends a lot of time looking deter these special horses. Race horse would be another group of animals who would likely befit from detailed understanding of the heart function during training. Anyone know a vet in the race horse world?
8. The market is quite large with 30,000 vets and likely more than 100 million dogs as pets in the USA. Vet are also very interested in new procedures and equipment, which will allow them to build their businesses.

Thank you for your continue support and interest. If you have any questions please contact me.

Regards,

Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
www.ventripoint.com
519-803-6937
<< Previous
Bullboard Posts
Next >>